Skip to main content

Research Repository

Advanced Search

Pre‐hospital transdermal glyceryl trinitrate for transient ischaemic attack: Data from the RIGHT ‐2 trial

Appleton, Jason P.; Dixon, Mark; Woodhouse, Lisa J.; Anderson, Craig S.; Ankolekar, Sandeep; Cala, Lesley; England, Timothy J.; Godolphin, Peter J.; Krishnan, Kailash; Mair, Grant; Muir, Keith W.; Potter, John; Price, Chris I.; Randall, Marc; Robinson, Thompson G.; Roffe, Christine; Rothwell, Peter M.; Sandset, Else Charlotte; Saver, Jeffrey L.; Siriwardena, A. Niroshan; Wardlaw, Joanna M.; Sprigg, Nikola; Bath, Philip M.

Authors

Jason P. Appleton

Mark Dixon

Lisa J. Woodhouse

Craig S. Anderson

Sandeep Ankolekar

Lesley Cala

Timothy J. England

Peter J. Godolphin

Kailash Krishnan

Grant Mair

Keith W. Muir

John Potter

Chris I. Price

Marc Randall

Thompson G. Robinson

Peter M. Rothwell

Else Charlotte Sandset

Jeffrey L. Saver

A. Niroshan Siriwardena

Joanna M. Wardlaw

Nikola Sprigg

Philip M. Bath



Abstract

Background and purpose: Ambulance trials assessing interventions in suspected stroke patients will recruit patients with currently active symptoms that will resolve into transient ischaemic attack (TIA). The safety and efficacy of glyceryl trinitrate (GTN) in the pre‐specified subgroup of patients with TIA in the Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial 2 (RIGHT‐2) was assessed. Methods: RIGHT‐2 was a pre‐hospital‐initiated multicentre randomized sham‐controlled blinded‐endpoint trial that randomized patients with presumed ultra‐acute stroke within 4 h of symptom onset to transdermal GTN or sham. Final diagnosis was determined by site investigators. The primary outcome was a shift in modified Rankin Scale (mRS) scores at 90 days analysed using ordinal logistic regression reported as adjusted common odds ratio with 95% confidence intervals (CIs). Secondary outcomes included death or dependence (mRS >2). Results: In all, 109 of 1149 (9.5%) patients had a final diagnosis of TIA (GTN 57, sham 52) with mean age 73 (SD 13) years, 19 (17.4%) had pre‐morbid mRS >2, and onset to randomization was 80 min (interquartile range 49, 105). GTN lowered blood pressure by 7.4/5.2 mmHg compared with sham by hospital arrival. At day 90, GTN had no effect on shift in mRS scores (common odds ratio for increased dependence 1.47, 95% CI 0.70–3.11) but was associated with increased death or dependence (mRS >2): GTN 29 (51.8%) versus sham 23 (46.9%), odds ratio 3.86 (95% CI 1.09–13.59). Conclusions: Pre‐hospital ultra‐acute transdermal GTN did not improve overall functional outcome in patients with investigator‐diagnosed TIA compared with sham treatment.

Citation

Appleton, J. P., Dixon, M., Woodhouse, L. J., Anderson, C. S., Ankolekar, S., Cala, L., …Bath, P. M. (in press). Pre‐hospital transdermal glyceryl trinitrate for transient ischaemic attack: Data from the RIGHT ‐2 trial. European Journal of Neurology, 31(11), 1-7. https://doi.org/10.1111/ene.16502

Journal Article Type Article
Acceptance Date Sep 17, 2024
Online Publication Date Oct 11, 2024
Deposit Date Oct 18, 2024
Publicly Available Date Oct 18, 2024
Journal European Journal of Neurology
Print ISSN 1351-5101
Electronic ISSN 1468-1331
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 31
Issue 11
Article Number e16502
Pages 1-7
DOI https://doi.org/10.1111/ene.16502
Keywords blood pressure, clinical trial, stroke, transient ischaemic attack
Public URL https://keele-repository.worktribe.com/output/950582
Publisher URL https://onlinelibrary.wiley.com/doi/10.1111/ene.16502

Files






You might also like



Downloadable Citations